Schonfeld Strategic Advisors’s Alzamend Neuro ALZN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23	Closed	-$97K	–	2110
2021 Q3	$97K	Buy	+23	New	+$126K	﹤0.01%	1948

Other funds holding ALZN

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

EGM

Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's ALZN Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Alzamend Neuro (ALZN) in Q4 2021, closing a stake of 23 shares — an estimated $97K sold.

Schonfeld Strategic Advisors first reported a position in ALZN in Q3 2021 and held it in 1 quarter. The position peaked at $97K in Q3 2021. 19 funds tracked by Wall St. Rank hold ALZN as of Q4 2021.

Schonfeld Strategic Advisors reported no remaining Alzamend Neuro position as of Q4 2021 after selling out during the quarter.
Schonfeld Strategic Advisors sold 23 Alzamend Neuro shares in Q4 2021, an estimated $97K.
Schonfeld Strategic Advisors first reported a position in Alzamend Neuro in Q3 2021 and held it in 1 quarter.
Schonfeld Strategic Advisors's Alzamend Neuro position peaked at $97K in Q3 2021.
19 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.